GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats
Authors
Keywords
Antipsychotics, Depression, GLP-1 receptor agonist, Olanzapine, Liraglutide
Journal
METABOLIC BRAIN DISEASE
Volume 30, Issue 2, Pages 519-527
Publisher
Springer Nature
Online
2014-07-14
DOI
10.1007/s11011-014-9591-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol
- (2014) Pelle L Ishøy et al. BMJ Open
- Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
- (2013) Pelle L. Ishøy et al. AMERICAN JOURNAL OF PSYCHIATRY
- Associations between obesogenic risk factors and depression among adolescents: a systematic review
- (2013) E. Hoare et al. Obesity Reviews
- Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis
- (2013) Tejashree S. Dixit et al. PHYSIOLOGY & BEHAVIOR
- Body composition and depressive/anxiety symptoms in overweight and obese individuals with metabolic syndrome
- (2013) Erika P Guedes et al. Diabetology & Metabolic Syndrome
- Acute sleep deprivation delays the glucagon-like peptide 1 peak response to breakfast in healthy men
- (2013) C Benedict et al. Nutrition & Diabetes
- Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits
- (2012) Bjørn H Ebdrup et al. BMC Medicine
- Retracted: Exendin-4 reverts behavioural and neurochemical dysfunction in a pre-motor rodent model of Parkinson's disease with noradrenergic deficit
- (2012) N Rampersaud et al. BRITISH JOURNAL OF PHARMACOLOGY
- Elevated Amylase and Lipase Levels in Patients Using Glucagonlike Peptide-1 Receptor Agonists or Dipeptidyl-Peptidase-4 Inhibitors in the Outpatient Setting
- (2012) Howard Lando et al. Endocrine Practice
- Exendin-4 treatment enhances L-DOPA evoked release of striatal dopamine and decreases dyskinetic movements in the 6-hydoxydopamine lesioned rat
- (2012) Amjad Abuirmeileh et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Rosiglitazone treatment reversed depression- but not psychosis-like behavior of db/db diabetic mice
- (2012) Ajaykumar N Sharma et al. JOURNAL OF PSYCHOPHARMACOLOGY
- RETRACTED: Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson’s disease with combined noradrenergic and serotonergic lesions
- (2012) N. Rampersaud et al. NEUROPEPTIDES
- Exendin-4 decreases amphetamine-induced locomotor activity
- (2012) Kevin Erreger et al. PHYSIOLOGY & BEHAVIOR
- The glucagon-like peptide 1 analogue Exendin-4 attenuates alcohol mediated behaviors in rodents
- (2012) Emil Egecioglu et al. PSYCHONEUROENDOCRINOLOGY
- Long-term Antipsychotic Treatment and Brain Volumes
- (2011) Beng-Choon Ho et al. ARCHIVES OF GENERAL PSYCHIATRY
- Neuroprotective effect of the glucagon-like peptide-1 receptor agonist, synthetic exendin-4, in streptozotocin-induced diabetic rats
- (2011) Wei Jing Liu et al. BRITISH JOURNAL OF PHARMACOLOGY
- Exendin-4, a Glucagon-Like Peptide-1 Receptor Agonist, Provides Neuroprotection in Mice Transient Focal Cerebral Ischemia
- (2011) Shinichiro Teramoto et al. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Incretin-based therapies
- (2011) Anthony H. STONEHOUSE et al. Journal of Diabetes
- Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat
- (2011) G. C. Smith et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- The glucagon-like peptide 1 receptor agonist exendin-4 improves reference memory performance and decreases immobility in the forced swim test
- (2010) Ruben Isacson et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Neurobehavioral deficits in db/db diabetic mice
- (2010) Ajaykumar N. Sharma et al. PHYSIOLOGY & BEHAVIOR
- Do antipsychotic medications reduce or increase mortality in schizophrenia? A critical appraisal of the FIN-11 study
- (2010) Marc De Hert et al. SCHIZOPHRENIA RESEARCH
- Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes
- (2010) P.I. Lin et al. SCHIZOPHRENIA RESEARCH
- Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
- (2009) Sehee Kim et al. JOURNAL OF ENDOCRINOLOGY
- Glucagon-like peptide 1 (7–36) amide (GLP-1) and exendin-4 stimulate serotonin release in rat hypothalamus
- (2008) Luigi Brunetti et al. PEPTIDES
- Quality of Life in Individuals With Serious Mental Illness and Type 2 Diabetes
- (2008) Faith Dickerson et al. PSYCHOSOMATICS
- The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
- (2008) Kirsten Lykkegaard et al. SCHIZOPHRENIA RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started